Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020:24:19.121.
doi: 10.7812/TPP/19.121. Epub 2020 Mar 13.

Drug-Induced Lupus, a One-time Hit or a Harbinger of Future Autoimmunity: A Case Report

Affiliations
Case Reports

Drug-Induced Lupus, a One-time Hit or a Harbinger of Future Autoimmunity: A Case Report

David Kirakossian et al. Perm J. 2020.

Abstract

Introduction: Drug-induced lupus (DIL) can comprise up to 10% of new lupus cases annually, and the list of medications associated with DIL is increasing. However, it can be difficult to recognize the connection between symptoms and a medication-induced autoimmune syndrome, which can lead to an invasive, costly workup. Given that the prognosis is usually good if therapy with the offending agent is stopped, it is important to identify this clinical entity promptly.

Case presentation: A healthy, 44-year-old man with hypertension was seen initially because of shoulder pain and again after development of fevers and chest pain. He underwent a thorough infectious workup and then oncologic workup, with his clinical course complicated by a Histoplasma infection. After evaluation by subspecialists, the patient was thought to have an autoimmune condition related to DIL. His symptoms improved after he discontinued the offending drug therapy and received a course of corticosteroids.

Discussion: Our case highlights how DIL should be on the differential when seemingly disparate symptoms develop in a patient receiving DIL-associated medications. Lupus is one of the "great imitators," in which symptoms can be ascribed to many different underlying causes. Although this patient's presentation may have been confounded by concomitant histoplasmosis, his improvement with cessation of hydralazine treatment argues in favor of DIL. His continued atypical serologic test results could be residual from his DIL and should normalize with time. However, it raises the question whether this bout of DIL has unmasked a previously quiescent autoimmune condition, requiring continued observation.

PubMed Disclaimer

Conflict of interest statement

Disclosure Statement

The author(s) have no conflicts of interest to disclose.

Similar articles

References

    1. Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA) J Autoimmun. 2014 Feb-Mar;48–49:66–72. doi: 10.1016/j.jaut.2014.01.005. - DOI - PubMed
    1. Araújo-Fernández S, Ahijón-Lana M, Isenberg DA. Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced. Lupus. 2014 May;23(6):545–53. doi: 10.1177/0961203314523871. - DOI - PubMed
    1. Vaglio A, Grayson PC, Fenaroli P, et al. Drug-induced lupus: Traditional and new concepts. Autoimmun Rev. 2018 Sep;17(9):912–8. doi: 10.1016/j.autrev.2018.03.016. - DOI - PubMed
    1. Kumar B, Strouse J, Swee M, Lenert P, Suneja M. Hydralazine-associated vasculitis: Overlapping features of drug-induced lupus and vasculitis. Semin Arthritis Rheum. 2018 Oct;48(2):283–7. doi: 10.1016/j.semarthrit.2018.01.005. - DOI - PubMed
    1. Iyer P, Dirweesh A, Zijoo R. Hydralazine induced lupus syndrome presenting with recurrent pericardial effusion and a negative antinuclear antibody. Case Rep Rheumatol. 2017;2017 doi: 10.1155/2017/5245904. - DOI - PMC - PubMed

Publication types

MeSH terms